Relmada Therapeutics, Inc. (RLMD) Stock

Relmada Therapeutics, Inc. (RLMD) is a Healthcare stock trading at $4.65 (as of 2026-08-21), with a market capitalization of $487.74M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company developing products for central nervous system diseases and other disorders. Its lead candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), an N-methyl-D-aspartate receptor antagonist in Phase 3 trials for major depressive disorder treatment in adults.

Understand Relmada Therapeutics, Inc.: how it makes money

Relmada Therapeutics is a clinical-stage biotechnology company developing therapies for central nervous system diseases and other disorders, with its lead candidate Esmethadone in Phase 3 trials for major depressive disorder; in the provided financial snapshot it reports 0.0B revenue.

The company’s profit potential is structurally driven by Phase 3 trial execution and success, because the provided operating readouts focus on clinical response, remission, durability, and trial enrollment capacity across its development programs.

Business quality (Weak): The provided data highlights strong trial outcome metrics for multiple candidate programs, but it also shows meaningful execution risk (for example, screening-related attrition) and the company remains pre-commercial in the provided snapshot.

Bull case

Phase 3 focused lead program in major depressive disorder: Esmethadone is described as being in Phase 3 trials for major depressive disorder in adults (adjunctive or monotherapy).
Strong provided month 12 outcomes in de novo patients: Clinical response at Month 12 (De Novo Patients) is 77.2%, and clinical remission at Month 12 (De Novo Patients) is 54.4%.
Durability-style endpoints appear in the provided KPIs: The provided operational metrics include durable complete response rates at twelve months in bladder cancer subtypes (for example, 76.0% and 80.0%).

Bear case

Clinical-stage risk and no reported revenue in the snapshot: The provided financial snapshot shows 0.0B revenue, which means there is no demonstrated product revenue generation in that period.
Screening and enrollment execution risk: The provided operational KPI includes a screen failure rate of 80.0%, which can limit the number of eligible patients and affect trial timelines.
Safety signal appears in the provided KPIs: The provided operational metric includes hematuria incidence (treatment-related) of 4.0%, which highlights potential tolerability considerations.

Valuation — source: SEC EDGAR (first-party)
Price	$4.65
Market Cap	$487.74M
Price / Book	2.23
Price / Sales	247.77

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$1.40M
Net Margin	-4110.7%
Revenue Growth (YoY)	-60.5%
EPS Growth (YoY)	-45.3%

Financial Health — source: SEC EDGAR
Altman Z-Score	27.72 (safe)

Valuation vs Sector & Industry
Sector P/E (Healthcare)	21.7
Industry P/E (Pharmaceutical Products)	17.2

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	Jupiter Topco LLC ($77.32M)
Institutional Holders Tracked	10
Congressional Trades (recent)	2

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Sergio Traversa
Employees	17
Country	US
IPO Date	2014-06-20

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.